Compare
GRAIL, Inc. vs Biodesix Inc vs BillionToOne, Inc. vs Personalis, Inc.
| Latest fiscal year | GRAIL, Inc. GRAL | Biodesix Inc BDSX | BillionToOne, Inc. BLLN | Personalis, Inc. PSNL |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $147.17M | $88.50M | $305.11M | $69.65M |
| Revenue growth (YoY) | +17.2% | +24.1% | +100.0% | -17.7% |
| Gross margin | n/a | n/a | 68.3% | 22.7% (computed) |
| Operating margin | -382.0% | -31.5% | 5.3% | -126.4% |
| Net margin | -277.5% | -39.8% | 2.4% | -116.7% |
| Net income | -$408.35M | -$35.27M | $7.45M | -$81.27M |
| EPS (Diluted) | -$11.11 | -$4.67 | $0.14 | -$0.91 |
| Operating cash flow | -$299.01M | -$23.27M | $24.59M | -$74.95M |
| Free cash flow | -$299.92M | -$23.53M | $15.71M | -$79.45M |
| Cash & equivalents | $249.73M | $18.99M | $495.98M | $124.25M |
| Total assets | $2.92B | $87.48M | $632.65M | $334.16M |
| Total liabilities | $344.15M | $89.94M | $152.55M | $72.98M |
| Shareholders' equity | $2.58B | -$2.46M | $480.11M | $261.19M |
| Return on year-end equity | -15.8% | n/a | 1.6% | -31.1% |
| Shares outstanding | n/a | 8.25M | n/a | 102.48M |
Revenue, most recent five fiscal years
| Fiscal year | GRAIL, Inc. | Biodesix Inc | BillionToOne, Inc. | Personalis, Inc. |
|---|---|---|---|---|
| Latest | $147.17M Ended 2025-12-31 | $88.50M Ended 2025-12-31 | $305.11M Ended 2025-12-31 | $69.65M Ended 2025-12-31 |
| 1 year earlier | $125.59M Ended 2024-12-31 | $71.32M Ended 2024-12-31 | $152.58M Ended 2024-12-31 | $84.61M Ended 2024-12-31 |
| 2 years earlier | $93.11M Ended 2023-12-31 | $49.09M Ended 2023-12-31 | $71.73M Ended 2023-12-31 | $73.48M Ended 2023-12-31 |
| 3 years earlier | $55.55M Ended 2023-01-01 | $38.21M Ended 2022-12-31 | n/a | $65.05M Ended 2022-12-31 |
| 4 years earlier | n/a | $54.51M Ended 2021-12-31 | n/a | $85.49M Ended 2021-12-31 |